top of page
News
Moroxite AB reports positive outcome on Xerafuse™ rhBMP-2 and Xerafuse™ Tobramycin study
Moroxite AB, a Swedish company specialized in innovative implants for spinal fusion, reports on positive outcome with complete spinal fusion for Xerafuse™ rhBMP-2 to replace autologous bone harvested from the patient’s iliac crest, and for Xerafuse™ Tobramycin as a bone graft extender to minimize post-operative infections. The study was conducted by researchers at Lund University, Sweden, based on Moroxite AB ´s bone mineral platform using Xerafuse™ bi-phasic ceramic bea
Nov 7
6-Month Follow-Up validates Zoledronic Acid and CaS/HA Augmentation for Enhanced Bone Formation in Osteoporotic Trochanteric Fractures
MD PhD Vetra Markevičiūtė , Department of Orthopedics and Traumatology, Lithuanian University of Health Sciences, Kaunas, has recently...
Sep 9
Dr. Xinggui Tian successfully defended his Ph.D. thesis
Dr. Xinggui Tian on June 24 2025 successfully defended his Ph.D. thesis “Advancing Spine Surgery with Innovative Applications of Calcium...
Aug 11
Moroxite AB granted Breakthrough Device Designation by U.S. FDA
We’re thrilled to announce that Moroxite AB has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA)...
May 27
bottom of page